Pembrolizumab vs Tofacitinib
Pembrolizumab vs Tofacitinib: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Tofacitinib.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days; Tofacitinib — 3.2 hours.
Chemical Properties
Molecular Formula: Tofacitinib — C16H20N6O.
Molecular Weight: Tofacitinib — 312.3700 g/mol.
Type: Pembrolizumab — Antibody; Tofacitinib — Small molecule.